---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-349107"
form_type: "8-K"
ticker: "KOD"
cik: "0001468748"
company_name: "Kodiak Sciences Inc."
filed_at: "2026-08-13T20:00:18+00:00"
generated_at: "2026-08-13T20:01:21.027748+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Kodiak Q2 net loss $65.6M; DAYBREAK topline due Sept 2026, cash into 2027

## Summary
- Q2 2026 net loss $65.6M ($1.05/sh) vs $54.3M ($1.03/sh) in Q2 2025; SBC $11.6M.
- Cash and equivalents $125.9M at June 30, 2026; expected to fund operations into 2027.
- R&D expense $56.1M (up from $42.8M) on PEAK/PINNACLE and manufacturing; G&A $10.8M.
- Phase 3 DAYBREAK topline (Zenkuda/KSI-501, wet AMD) expected Sept 2026; PEAK Pivotal Analysis 1 (KSI-101, MESI) Dec 2026.
- Enrollment completed for first 300-patient PEAK cohort; ALTO Phase 3 (KSI-501 vs aflibercept, DME) patient enrollment initiated.

## SEC filing metadata
- accession: 0001193125-26-349107
- form_type: 8-K
- ticker: KOD
- cik: 0001468748
- company_name: Kodiak Sciences Inc.
- filed_at: 2026-08-13T20:00:18+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1468748/000119312526349107/0001193125-26-349107-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1468748/000119312526349107/kod-20260813.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-349107
- JSON: https://secwatch.observer/filing/0001193125-26-349107.json
- Plain text: https://secwatch.observer/filing/0001193125-26-349107.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.